Clinical trials: Comorbidities
Lymphocytic Leukemia, Chronic
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of obinutuzumab (RO5072759) in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT01010061
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with…
- Trial name
- NCT06672939
- Testing
- Orforglipron
- Where
- 34 sites in United States, Israel and 4 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Obesity or Overweight
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults…
- Trial name
- COMO-1 (NCT06867718)
- Testing
- RGT001-075
- Where
- 35 sites in United States
- Volunteers
- 267 people
- Sponsor
- Regor Pharmaceuticals Inc.
Psoriasis
Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis
W11-050 is a Mexican open label multicenter study that has been designed to further assess the safety and efficacy of adalimumab in the treatment of patients with active plaque psoriasis who have failed prior conventional…
- Trial name
- NCT01265823
- Testing
- Adalimumab
- Where
- 8 sites in Mexico
- Volunteers
- 150 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Obesity, Overweight
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
- Trial name
- NCT04881760
- Testing
- LY3437943
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 338 people
- Sponsor
- Eli Lilly and Company
B-Cell Chronic Lymphocytic Leukemia
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
This multicenter, double-blind, randomized, placebo-controlled study will evaluate the safety of a single infusion of tocilizumab versus placebo, administered in addition to standard premedications (antipyretic, antihistamine…
- Trial name
- NCT02336048
- Testing
- Chlorambucil, Obinutuzumab, Standard Premedication
- Where
- 14 sites in Israel, Italy and 3 more
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Obesity, Overweight
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
- Trial name
- EVOLVE-2 (NCT07281937)
- Testing
- VRB-101
- Where
- 22 sites in United States
- Volunteers
- 206 people
- Sponsor
- Verdiva Bio Dev Limited
Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
- Trial name
- NCT07836270
- Testing
- Ecnoglutide Injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Severe Aortic Stenosis
Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement
To evaluate the safety and efficacy of the Medtronic CoreValve® System for the treatment of symptomatic severe aortic stenosis in subjects with significant comorbidities in whom the risk of surgical aortic valve replacement has a…
- Trial name
- NCT01675440
- Testing
- Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
- Where
- 43 sites in United States
- Volunteers
- 782 people
- Sponsor
- Medtronic Cardiovascular
Chronic Kidney Disease
Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.
Researchers in this study want to learn more about the safety of the drug runcaciguat and how well it works when given at the highest dose as tolerated by the individual patient whose kidneys are not working properly and…
- Trial name
- CONCORD (NCT04507061)
- Testing
- runcaciguat
- Where
- 71 sites in Austria, Belgium and 11 more
- Volunteers
- 243 people
- Sponsor
- Bayer
Obesity, Overweight and Obesity
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
- Trial name
- NCT05051579
- Testing
- LY3502970
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.
- Trial name
- NCT06047548
- Testing
- Tirzepatide
- Where
- 20 sites in United States
- Volunteers
- 441 people
- Sponsor
- Eli Lilly and Company
Obese Adults
A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities
The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.
- Trial name
- NCT07838740
- Testing
- VK2735 Drug
- Where
- 2 sites in United States
- Volunteers
- 270 people
- Sponsor
- Viking Therapeutics, Inc.
Obesity or Overweight, Weight-Related Comorbidity
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
- Conditions
- Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
- Trial name
- SELENE 3 (NCT07776509)
- Testing
- Lenbelintide
- Where
- 96 sites in United States, Argentina and 9 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Renal Anemia of Chronic Kidney Disease
A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)
This prospective, multicenter, observational study will evaluate the impact of comorbidity factors on the hemoglobin level in participants with chronic kidney disease who are not on dialysis and initiated on treatment with…
- Trial name
- NCT01756612
- Testing
- Methoxy Polyethylene Glycol-Epoetin Beta
- Where
- 108 sites in France
- Volunteers
- 551 people
- Sponsor
- Hoffmann-La Roche
Lymphocytic Leukemia, Chronic
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of (obinutuzumab) RO5072759 in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with…
- Trial name
- NCT02053610
- Testing
- obinutuzumab, rituximab, chlorambucil
- Where
- 261 sites in United States, Argentina and 24 more
- Volunteers
- 787 people
- Sponsor
- Hoffmann-La Roche
Complicated Skin and Soft Tissue Infection
Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.
The purpose of this study is to evaluate the effects of Ceftaroline Fosamil versus Vancomycin plus Aztreonam in treatment of patients with complicated bacterial skin and soft tissue infections.
- Trial name
- NCT02202135
- Testing
- Ceftaroline fosamil, Vancomycin, Aztreonam
- Where
- 22 sites in Argentina, Brazil and 11 more
- Volunteers
- 4 people
- Sponsor
- Pfizer
Obesity
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
- Trial name
- ZUPREME (NCT06662539)
- Testing
- Petrelintide
- Where
- 32 sites in United States, Poland and 1 more
- Volunteers
- 493 people
- Sponsor
- Zealand Pharma
Obesity, Overweight
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program.
- Trial name
- SURMOUNT-3 (NCT04657016)
- Testing
- Tirzepatide
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 579 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/topiramate in Overweight Comorbidities/obesity
An observational, multicenter, national study with retrospective real-life data collection on the combined treatment of sibutramine and topiramate (off-label use) for the treatment of overweight with comorbidity(ies) or obesity.
- Trial name
- TOLERASIT (NCT05209997)
- Testing
- Source document data collection
- Where
- 2 sites in Brazil
- Sponsor
- Eurofarma Laboratorios S.A.